Shares Of Vical Tumbled 43% After Reporting Failed Results In Herpes Vaccine

Shares of Vical (VICL) closed down 43% today after the company reported negative results in its Phase 1/2 trial in patients with Herpes.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.